AbbVie: Xilio Therapeutics' $2.1 Billion Collaboration With AbbVie
Latham & Watkins advised AbbVie on the transaction, and Ropes & Gray advised Xilio Therapeutics. Xilio Therapeutics (Nasdaq: XLO) announced a strategic collaboration and option agreement [...]
Read full article »
AbbVie is an Illinois-based biopharmaceutical company that develops and markets medicinal drugs for the treatment of neurodegenerative diseases and cancer.
Read more